Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Zivar SALEHI |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
How matrix metalloproteinase (MMP)-9 (rs3918242) polymorphism affects MMP-9 serum concentration and associates with autism spectrum disorders: A case-control study in Iranian population / Javid Rezaei LORD in Development and Psychopathology, 34-3 (August 2022)
[article]
Titre : How matrix metalloproteinase (MMP)-9 (rs3918242) polymorphism affects MMP-9 serum concentration and associates with autism spectrum disorders: A case-control study in Iranian population Type de document : Texte imprimé et/ou numérique Auteurs : Javid Rezaei LORD, Auteur ; Farhad MASHAYEKHI, Auteur ; Zivar SALEHI, Auteur Article en page(s) : p.882-888 Langues : Anglais (eng) Mots-clés : autism spectrum disorders gene polymorphism MMP-9 serum Index. décimale : PER Périodiques Résumé : The aim of this project was to evaluate the relationship of matrix metalloproteinase-9 (MMP-9) genetic variation and its serum concentration with autism spectrum disorder (ASD). One hundred ASD and 120 controls were enrolled in this study. Genomic DNA was extracted from blood and MMP-9 polymorphism was determined by polymerase chain reaction restriction fragment length polymorphism and serum levels were measured by enzyme-linked immunosorbent assay. The frequencies of CC, CT, and TT genotypes were 72%, 26%, and 2% in controls and 31%, 57%, and 12% in ASD, respectively. The frequencies of C and T alleles in ASD were 59.5% and 40.5%, and controls were 86% and 14%, respectively. There is a significant increase in serum MMP-9 levels in ASD as compared to controls. We have also shown that TT genotype is significantly associated with increase serum MMP-9 levels in patients (TT, CT, and CC serum levels were 91.77 Â+ 10.53, 70.66 Â+ 7.21, and 38.66 Â+ 5.52 and in controls were 55.55 Â+ 11.39, 42.66 Â+ 7.85, and 30.55 Â+ 6.34 ng/ml, respectively). It is concluded that there is a significant association between rs3918242 MMP-9 polymorphism and its serum concentration with autism. We also suggest that TT genotype is associated with increased MMP9 expression and may be a risk factor for ASD. En ligne : http://dx.doi.org/10.1017/S0954579420002102 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=484
in Development and Psychopathology > 34-3 (August 2022) . - p.882-888[article] How matrix metalloproteinase (MMP)-9 (rs3918242) polymorphism affects MMP-9 serum concentration and associates with autism spectrum disorders: A case-control study in Iranian population [Texte imprimé et/ou numérique] / Javid Rezaei LORD, Auteur ; Farhad MASHAYEKHI, Auteur ; Zivar SALEHI, Auteur . - p.882-888.
Langues : Anglais (eng)
in Development and Psychopathology > 34-3 (August 2022) . - p.882-888
Mots-clés : autism spectrum disorders gene polymorphism MMP-9 serum Index. décimale : PER Périodiques Résumé : The aim of this project was to evaluate the relationship of matrix metalloproteinase-9 (MMP-9) genetic variation and its serum concentration with autism spectrum disorder (ASD). One hundred ASD and 120 controls were enrolled in this study. Genomic DNA was extracted from blood and MMP-9 polymorphism was determined by polymerase chain reaction restriction fragment length polymorphism and serum levels were measured by enzyme-linked immunosorbent assay. The frequencies of CC, CT, and TT genotypes were 72%, 26%, and 2% in controls and 31%, 57%, and 12% in ASD, respectively. The frequencies of C and T alleles in ASD were 59.5% and 40.5%, and controls were 86% and 14%, respectively. There is a significant increase in serum MMP-9 levels in ASD as compared to controls. We have also shown that TT genotype is significantly associated with increase serum MMP-9 levels in patients (TT, CT, and CC serum levels were 91.77 Â+ 10.53, 70.66 Â+ 7.21, and 38.66 Â+ 5.52 and in controls were 55.55 Â+ 11.39, 42.66 Â+ 7.85, and 30.55 Â+ 6.34 ng/ml, respectively). It is concluded that there is a significant association between rs3918242 MMP-9 polymorphism and its serum concentration with autism. We also suggest that TT genotype is associated with increased MMP9 expression and may be a risk factor for ASD. En ligne : http://dx.doi.org/10.1017/S0954579420002102 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=484